Products for Research Use Only

Iproniazid (phosphate)

CAT: 0804-HY-B0886-01Size: 50 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0886-01Size:50 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Iproniazid phosphate is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid phosphate inhibits MAO activity and enhances Rotenone -induced Apoptosis. Iproniazid phosphate modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid phosphate can be used in the research of depression, Parkinson's disease, and hepatotoxicity[1][2][3][4][5][6][7].
CAS Number
305-33-9
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Monoamine Oxidase
Type
Reference compound
Related Pathways
Apoptosis; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Endocrinology; Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Iproniazid-phosphate.html
Purity
99.92
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL
Smiles
O=C(C1=CC=NC=C1)NNC(C)C.O=P(O)(O)O
Molecular Formula
C9H16N3O5P
Molecular Weight
277.21
Precautions
H302, H315, H319, H335
References & Citations
[1]Fagervall I, et al. Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors. Biochemical pharmacology 35 (8) : 1381–1387|[2]Watabe M, et al. Mitochondrial complex I inhibitor rotenone-elicited dopamine redistribution from vesicles to cytosol in human dopaminergic SH-SY5Y cells. J Pharmacol Exp Ther. 2007 Nov;323 (2) :499-507. |[3]Dodson AM, et al. Serotonin uptake and metabolism by cultured guinea pig airway smooth muscle cells. Pulm Pharmacol Ther. 2004;17 (1) :19-25. |[4]De Oliveira LF, et al. Effects of 5-hydroxytryptophan, iproniazid and p-chlorophenylalanine on lidocaine seizure threshold of mice. Eur J Pharmacol. 1974 Nov;29 (1) :5-9. |[5]Nelson SD, et al. Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine. J Pharmacol Exp Ther. 1978 Sep;206 (3) :574-85. |[6]SETNIKAR I V O, et al. Retardation of sexual development in female rats due to iproniazid treatment. Endocrinology, 1960, 67 (4) : 511-520. |[7]Huang J T, et al. The effect of pretreatment with iproniazid on the behavioral activities of β-phenylethylamine in rats. Psychopharmacologia, 1974, 35 (1) : 77-81.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched

Chemical Information

Iproniazid Phosphate
CAS Number305-33-9
PubChem CID9367
IUPAC Namephosphoric acid;N'-propan-2-ylpyridine-4-carbohydrazide
Molecular FormulaC9H16N3O5P
Molecular Weight277.21
Topological Polar Surface Area132
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count7
Rotatable Bond Count3
Heavy Atom Count18
Formal Charge0
Complexity214
SMILES
CC(C)NNC(=O)C1=CC=NC=C1.OP(=O)(O)O
InChI
InChI=1S/C9H13N3O.H3O4P/c1-7(2)11-12-9(13)8-3-5-10-6-4-8;1-5(2,3)4/h3-7,11H,1-2H3,(H,12,13);(H3,1,2,3,4)
InChIKey
YPDVTKJXVHYWFY-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Iproniazid Phosphate
CAS: 305-33-9
CID: 9367
Formula: C9H16N3O5P
MW: 277.21
Interactive 3D Structure
Loading 3D structure...